Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in predicting response to chemotherapy in samples from young patients with osteosarcoma.
Drug: systemic chemotherapy
Genetic: DNA methylation analysis
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis
Other: medical chart review
|Official Title:||Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma|
- Methylated status as predictor of response to neoadjuvant chemotherapy [ Designated as safety issue: No ]
|Study Start Date:||July 2011|
|Estimated Primary Completion Date:||September 2011 (Final data collection date for primary outcome measure)|
- Determine whether methylation status predicts response to neoadjuvant chemotherapy in samples from children and young adults with osteosarcoma.
OUTLINE: Patients are stratified according to response to neoadjuvant chemotherapy (good vs poor).
DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by Ligation-mediated PCR and mass-array genotyping.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01374672
|Principal Investigator:||Jeremy Rosenblum, MD||Albert Einstein College of Medicine of Yeshiva University|